Grundinformationen
- Standard-SMILES
O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1- InChIKey
LPEPZBJOKDYZAD-UHFFFAOYSA-N- Summenformel
- C14H10F3NO2
- Durchschnittliche Molmasse
- 281,23 g/mol
- Monoisotopische Masse
- 281,06636322
Überblick
Flufenamic acid is an aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is an aromatic amino acid and an organofluorine compound. It is functionally related to an anthranilic acid, a (trifluoromethyl)benzene and a diphenylamine. It is a conjugate acid of a flufenamate.
Namen und Bezeichner
- Bevorzugter Name
- Flufenamic Acid
- IUPAC
- 2-[3-(trifluoromethyl)anilino]benzoic acid
- Lokaler Name
- 2-((3-(Trifluormethyl)phenyl)-amino)benzoesäure
- Englischer Name
- Flufenamic acid
- Summenformel
- C14H10F3NO2
- Molmasse
- 281.23
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
530-78-9- PubChem CID
- 3371
- DTXSID
DTXSID7023063- ChEMBL
CHEMBL23588- ChEBI
CHEBI:42638- UNII
- 60GCX7Y6BH
- EC Number
- 208-494-1
- Nikkaji
- J2.064H
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 5,2
- Polarare Oberfläche (TPSA)
- 49,3 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 6
- Frei drehbare Bindungen
- 3
- Schwere Atome
- 20
- Formalladung
- 0
- Komplexität
- 346
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals
Pharmaceuticals -> Musculo-skeletal system -> Anti-inflammatory and antirheumatic products
Pharmaceuticals -> Listed in ZINC15
Physikochemische Eigenschaften
- Schmelzpunkt
- 132 · 132-135 °C(lit.)
- Siedepunkt
- 373.9 · 373.9±42.0 °C(Predicted)
- Dichte
- 1.338 · 1.3380 (estimate)
- Dampfdruck
- 0 Pa · 0Pa at 25℃
- storage temp.
- Keep in dark place,Inert atmosphere,Room temperature
- Löslichkeit
- 11 · soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of flufenamic acid in these solvents is approximately 11, 39, and 59 mg/ml, respectively.
- pka
- 3.9 · pKa 3.9 (Uncertain);3.85 (Uncertain)
- Aggregatzustand
- Crystalline Powder or Chunks
- Farbe
- Off-white to gray-green
- Wasserlöslichkeit
- 0.0265 g/L · 0.0265 g/L (37 ºC)
- Merck
- 14 · 14,4132
- BRN
- 1996069 · 1996069
- Major Application
- forensics and toxicologypharmaceutical (small molecule)veterinary
- InChI
- 1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)
- InChIKey
- LPEPZBJOKDYZAD-UHFFFAOYSA-N
- SMILES
- OC(=O)c1ccccc1Nc2cccc(c2)C(F)(F)F
- LogP
- 5.25 · 5.25
- CAS Datenbank
- 530 · 530-78-9(CAS DataBase Reference)
- NIST chemische Informationen
- Flufenamic acid(530-78-9)
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 0.8% (1 of 120) of reports.
Danger
H301 (95.8%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 120 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Sicherheitsdaten
- wgk
- 3
- ridadr
- UN 2811 6.1/PG 3
- hs_code
- 29224999
- RTECS-Nr.
- CB4375000
- risk_code
- 22-36/38
- Toxizität
- LD50 in mice: 715 mg/kg orally (Zoni)
- hazard_code
- Xn
- safety_code
- 26
- hazard_class
- 6.1(b)
- packing_group
- III
- Speicherklasse
- 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
- Hazard Classifications
- Acute Tox. 3 OralEye Irrit. 2Skin Irrit. 2
Chemie und Industrie
Pharmakologische Informationen
ATC Code
M - Musculo-skeletal system
QM - Musculo-skeletal system
Verwendung und Herstellung
Anwendungen
VerwendenFlufenamic acid is used for moderate pain and dysmenorrhea, but it should not be used for more than 1 week due to the possibility of nephrotoxicity, gastrointestinal toxicity, and anemia. It is frequently used in combination with the anticoagulant warfarin, the effect of which is strengthened when combined with flufenamic acid.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Nachgelagerte Produkte
Anbieter50 Anbieter
Zugehörige Reaktionen
Verknüpfte Notizen
Wird geladen…